Abstract
An ideal vaccine against SARS-CoV-2 is expected to elicit broad immunity to prevent viral infection and disease, with efficient viral clearance in the upper respiratory tract (URT). Here, the N protein and prefusion-full S protein (SFLmut) are combined with flagellin (KF) and cyclic GMP-AMP (cGAMP) to generate a candidate vaccine, and this vaccine elicits stronger systemic and mucosal humoral immunity than vaccines containing other forms of the S protein. Furthermore, the candidate vaccine administered via intranasal route can enhance local immune responses in the respiratory tract. Importantly, human ACE2 transgenic mice given the candidate vaccine are protected against lethal SARS-CoV-2 challenge, with superior protection in the URT compared with that in mice immunized with an inactivated vaccine. In summary, the developed vaccine can elicit a multifaceted immune response and induce robust viral clearance in the URT, which makes it a potential vaccine for preventing disease and infection of SARS-CoV-2.
Keywords:
SARS-CoV-2; SFL(mut); cGAMP; flagellin; mucosal immunity; nucleocapsid; protective efficacy.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adjuvants, Vaccine
-
Administration, Intranasal
-
Angiotensin-Converting Enzyme 2 / immunology
-
Angiotensin-Converting Enzyme 2 / metabolism
-
Animals
-
Antibodies, Viral / immunology
-
Antigens / immunology
-
COVID-19 / immunology
-
COVID-19 / prevention & control
-
COVID-19 Vaccines / genetics
-
COVID-19 Vaccines / immunology*
-
Chlorocebus aethiops
-
Combined Modality Therapy / methods*
-
Coronavirus Nucleocapsid Proteins / immunology
-
Female
-
Flagellin / immunology
-
HEK293 Cells
-
Humans
-
Immunity / immunology
-
Immunity / physiology
-
Immunity, Humoral / immunology
-
Immunization
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Transgenic
-
Nucleotides, Cyclic / immunology
-
Phosphoproteins / immunology
-
SARS-CoV-2 / immunology*
-
SARS-CoV-2 / pathogenicity
-
Spike Glycoprotein, Coronavirus / immunology
-
Vaccination
-
Vero Cells
Substances
-
Adjuvants, Vaccine
-
Antibodies, Viral
-
Antigens
-
COVID-19 Vaccines
-
Coronavirus Nucleocapsid Proteins
-
Nucleotides, Cyclic
-
Phosphoproteins
-
Spike Glycoprotein, Coronavirus
-
cyclic guanosine monophosphate-adenosine monophosphate
-
nucleocapsid phosphoprotein, SARS-CoV-2
-
spike protein, SARS-CoV-2
-
Flagellin
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2